返回
A
Andrew L. Johnson
university of pennsylvania
32H指数
145论文数
4.7K被引数
收录论文 33
发表时间
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a VodcastII期COPERNICUS研究:皮下注射Amivantamab联合Lazertinib作为一线治疗,或与化疗联合作为二线治疗,用于EGFR突变非小细胞肺癌的播客视频
Oncology and Therapy
IF3.2

